Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
BioLine Rx's Sloan Ratio for the quarter that ended in Dec. 2023 was -61.71%.
Warning Sign:
When sloan ratio (-61.71)% higher than 25% or lower than -25%, earnings are more likely to be made up of accruals.
As of Dec. 2023, BioLine Rx has a Sloan Ratio of -61.71%, indicating earnings are more likely to be made up of accruals.
BioLine Rx Sloan Ratio % Historical Data
The historical data trend for BioLine Rx's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of BioLine Rx's Sloan Ratio %
For the Biotechnology subindustry, BioLine Rx's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioLine Rx's Sloan Ratio % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioLine Rx's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where BioLine Rx's Sloan Ratio % falls into.
BioLine Rx Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
BioLine Rx's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as
BioLine Rx's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was -12.162 (Mar. 2023 ) + -18.545 (Jun. 2023 ) + -16.023 (Sep. 2023 ) + -13.884 (Dec. 2023 ) = $-60.61 Mil.
BioLine Rx's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was -8.016 (Mar. 2023 ) + -9.682 (Jun. 2023 ) + -9.901 (Sep. 2023 ) + 4.991 (Dec. 2023 ) = $-22.61 Mil.
BioLine Rx's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 was 6.642 (Mar. 2023 ) + 11.1 (Jun. 2023 ) + 4.097 (Sep. 2023 ) + -20.395 (Dec. 2023 ) = $1.44 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioLine Rx (NAS:BLRX) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Dec. 2023, BioLine Rx has a Sloan Ratio of -61.71%, indicating earnings are more likely to be made up of accruals.
BioLine Rx Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of BioLine Rx's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BLRX has been successfully added to your 